8月26日，科美诊断跌0.11%，成交额4936.07万元。两融数据显示，当日科美诊断获融资买入额729.97 万元，融资偿还952.85万元，融资净买入-222.88万元。截至8月26日，科美诊断融资融券余额合计2.06 亿元。 融资方面，科美诊断当日融资买入729.97万元。当前融资余额2.06亿元，占流通市值的5.86%，融资余 额超过近一年90%分位水平，处于高位。 资料显示，科美诊断技术股份有限公司位于北京市海淀区永丰基地丰贤中路7号北科现代制造园孵化楼 一层、六层，成立日期2007年5月10日，上市日期2021年4月9日，公司主营业务涉及临床免疫化学发光 诊断检测试剂和仪器的研发、生产和销售。主营业务收入构成为：LiCA系列产品92.04%，CC系列产品 7.96%。 截至3月31日，科美诊断股东户数1.10万，较上期增加14.69%；人均流通股36384股，较上期减少 12.81%。2025年1月-3月，科美诊断实现营业收入8130.01万元，同比减少27.01%；归母净利润1454.28万 元，同比减少62.12%。 分红方面，科美诊断A股上市后累计派现3.06亿元。近三年，累计派现2.38亿 ...

最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断32.3326.262.3333.37亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18.2218.241.5139.27亿9奥泰生物18.4419.441.4958.81亿10维力医疗18.4719.732.3243.29亿11鱼跃医疗 20.1919.802.73357.58亿12安图生物20.6219.682.65235.08亿 来源：金融界 股东方面，截 ...

8月1日，科美诊断今日收盘8.49元，上涨6.66%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到32.99倍，创113天以来新低，总市值34.05亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.65倍，行业中值37.22倍，科美诊断排 名第68位。 股东方面，截至2025年3月31日，科美诊断股东户数11024户，较上次增加1412户，户均持股市值35.28 万元，户均持股数量2.76万股。 科美诊断技术股份有限公司的主营业务是临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售。 公司的主要产品是LiCA系列产品、CC系列产品。报告期内，公司新获得境内外授权专利64项，其中境 内发明专利33项，境内实用新型专利20项，外观设计专利11项。展现出公司持续壮大的创新能力和技术 储备。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断32.9926.802.3834.05亿行业平均 53.655 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a significant decline in revenue and net profit in the latest quarterly report [1][2] - Kemei Diagnostics' stock closed at 7.99 yuan, with a rolling PE ratio of 31.05, marking a new low in 90 days, and a total market capitalization of 3.205 billion yuan [1] - The company ranks 63rd in the medical device industry, which has an average PE ratio of 55.28 and a median of 38.06 [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its growing innovation capability and technological reserves [1] Group 3 - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics, which has a current PE ratio of 30.46, significantly lower than the industry average of 54.56 [1][2] - Kemei Diagnostics has a total market capitalization of 3.145 billion yuan, ranking 62nd in the medical device industry based on PE ratio [1][2] - The company has seen an increase in shareholder numbers, with 11,024 shareholders as of March 31, 2025, an increase of 1,412 from the previous count [1] Group 2 - Kemei Diagnostics specializes in the research, development, production, and sales of clinical immunochemistry diagnostic reagents and instruments, with key products including the LiCA and CC series [1] - The company has demonstrated strong innovation capabilities, acquiring 64 new domestic and international patents during the reporting period, including 33 domestic invention patents [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported a revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12% [1]

7月18日，科美诊断今日收盘7.73元，上涨2.11%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到30.04倍，创77天以来新低，总市值31.01亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均52.34倍，行业中值36.99倍，科美诊断排 名第64位。 股东方面，截至2025年3月31日，科美诊断股东户数11024户，较上次增加1412户，户均持股市值35.28 万元，户均持股数量2.76万股。 科美诊断技术股份有限公司的主营业务是临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售。 公司的主要产品是LiCA系列产品、CC系列产品。报告期内，公司新获得境内外授权专利64项，其中境 内发明专利33项，境内实用新型专利20项，外观设计专利11项。展现出公司持续壮大的创新能力和技术 储备。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断30.0424.402.1731.01亿行业平均 52.344 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics in the medical device industry, indicating a lower PE ratio compared to industry averages [1][2] - Kemei Diagnostics closed at 7.11 yuan, with a PE ratio of 27.63, while the industry average PE is 48.89 [1][2] - The company's total market capitalization is 2.852 billion yuan, ranking 64th in the industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, nine institutions hold shares in Kemei Diagnostics, with a total holding of 206.2876 million shares valued at 1.537 billion yuan [1] - The main business of Kemei Diagnostics includes the research, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its innovation capabilities [1] Group 3 - In the latest performance report for the first quarter of 2025, Kemei Diagnostics reported revenue of 81.3001 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5428 million yuan, down 62.12% [1] - The gross profit margin for the company stands at 66.88% [1]